Millie Das, MD

Even with consolidation immunotherapy, most limited-stage patients still recur, a reminder that biomarker-driven approaches, earlier detection, and next-generation agents remain essential to moving survival further.

Logistics, not efficacy, often decide who completes limited-stage treatment. Distance from infusion centers, caregiver support, and clinic workflows can matter as much as the medicine itself in determining outcomes.

Despite a clear survival benefit, a meaningful share of eligible patients never receive consolidation immunotherapy after chemoradiation, exposing a gap between what trial data supports and what real-world practice actually delivers.

The ADRIATIC trial reshaped limited-stage treatment, extending median survival by nearly two years with consolidation immunotherapy, a shift so significant that adherence, not efficacy, is now the field's central clinical challenge.

Concurrent chemoradiotherapy remains curative-intent therapy for limited-stage disease, yet cure rates without immunotherapy stall near thirty percent, a ceiling that scheduling choices and careful monitoring can only partly raise on their own.

Small cell lung cancer's stark divide between curable, localized disease and systemic, incurable disease shapes every treatment decision that follows, and screening gains are slowly shifting how many patients get caught early enough to benefit.